This review evaluates the diagnostic value of multiparametric MRI (mpMRI) and prostate-specific membrane antigen-targeted PET/CT (PSMA-targeted PET/CT) for restaging radiorecurrent prostate cancer.<h4>Methods</h4>A narrative review was conducted using PubMed and Scopus. The gene discussed is FOLH1; the disease is prostate carcinoma.